# Safety of Everolimus and Pemetrexed in Lung Cancer Patients

> **NCT00434174** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 48 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Everolimus
- **DRUG:** Pemetrexed

## Key facts

- **NCT ID:** NCT00434174
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** 2010-12
- **Final completion:** 2010-12
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2020-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00434174

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00434174, "Safety of Everolimus and Pemetrexed in Lung Cancer Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00434174. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*